The Effect of High Dose Rate Brachytherapy in Combination with External Beam Radiotherapy on Men's Health-related Quality of Life and Sexual Function over a 2 Year Time Span

被引:7
作者
Conaglen, H. M. [1 ]
de Jong, D. [2 ]
Hartopeanu, C. [3 ]
Conaglen, J. V. [1 ]
Tyrie, L. K. [3 ]
机构
[1] Univ Auckland, Waikato Clin Sch, Sexual Hlth Res Unit, Hamilton, New Zealand
[2] Univ Waikato, Hamilton, New Zealand
[3] Waikato Hosp, Hamilton, New Zealand
关键词
Androgen deprivation therapy; external beam radiotherapy; high dose rate brachytherapy; prostate cancer; quality of life; sexual function; LOCALIZED PROSTATE-CANCER; ERECTILE FUNCTION IIEF-5; ANDROGEN DEPRIVATION; INTERNATIONAL INDEX; DIAGNOSTIC-TOOL; THERAPY;
D O I
10.1016/j.clon.2012.10.012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To investigate changes in health-related quality of life and sexual function in men after high dose rate (HDR) brachytherapy and external beam radiotherapy (EBRT), with or without androgen deprivation therapy, for localised prostate cancer. Materials and methods: Eligible men who had undergone HDR brachytherapy/EBRT for their prostate cancer completed questionnaires before any treatment (baseline) and at 3 monthly intervals. The European Organization for Research and Treatment of Cancer (EORTC) C30 quality of life measure (QLQ-C30), the PR25 prostate-specific supplement and the International Index of Erectile Function-Short Form CHEF-SF) were completed. An analysis of changes from baseline to 2 years, for the 87 men who completed surveys, was carried out. Results: The mean EORTC QLQ-C30 quality of life scores, urinary, bowel and sexual symptoms had all improved. However, improvements did not return men to baseline levels at 2 years. Sexual function as measured by both scales was least likely to recover. There were no differences due to androgen deprivation therapy. Minimally important differences were still reported by men at 2 years as follows: urinary (36%), bowel (24%), hormone treatment side-effects (40%), IIEF-SF (55%). Discrepancies between mean and minimally important differences changes are explained by some men remaining more affected by their therapy than others. Conclusion: The findings do not support our first hypothesis that urinary, bowel and sexual problems in these men will return to baseline levels once therapy is completed and 2 years have elapsed. Our findings indicate the changes men experience are significant, do occur early, and many do not resolve in the longer term. (C) 2012 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:197 / 204
页数:8
相关论文
共 37 条
  • [31] Prospective longitudinal comparative study of health-related quality of life and treatment satisfaction in patients treated with hormone therapy, radical retropubic prostatectomy, and high or low dose rate brachytherapy for prostate cancer
    Miwa, Sotaro
    Mizokami, Atsushi
    Konaka, Hiroyuki
    Ueno, Satoru
    Kitagawa, Yasuhide
    Koh, Eitetsu
    Namiki, Mikio
    PROSTATE INTERNATIONAL, 2013, 1 (03) : 117 - 124
  • [32] Patient-reported health-related quality of life for men treated with low-dose-rate prostate brachytherapy as monotherapy with 125-iodine, 103-palladium, or 131-cesium: Results of a prospective phase II study
    Blanchard, Pierre
    Pugh, Thomas J.
    Swanson, David A.
    Mahmood, Usama
    Chen, Hsiang-Chun
    Wang, Xuemei
    Graber, William J.
    Kudchadker, Rajat J.
    Bruno, Teresa
    Feeley, Thomas
    Frank, Steven J.
    BRACHYTHERAPY, 2018, 17 (02) : 265 - 276
  • [33] Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with 192IR brachytherapy:: A prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25
    Wahlgren, T
    Brandberg, Y
    Häggarth, L
    Hellström, M
    Nilsson, S
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : 51 - 59
  • [34] Acute toxicity and health-related quality of life outcomes of localized prostate cancer patients treated with magnetic resonance imaging-guided high-dose-rate brachytherapy: A prospective phase II trial
    Sanmamed, Noelia
    Adleman, Jenna
    Berlin, Alejandro
    Borg, Jette
    Lao, Bernadeth
    Weersink, Robert
    Simeonov, Anna
    Rink, Alex
    Beiki-Ardakani, Akbar
    Menard, Cynthia
    Chung, Peter
    Helou, Joelle
    BRACHYTHERAPY, 2023, 22 (01) : 58 - 65
  • [35] Health-related quality of life and patient-reported symptoms after postoperative proton beam radiotherapy of cervical and endometrial cancer: 2-year results of the prospective phase II APROVE-trial
    Eva Meixner
    Antje Wark
    Tobias Forster
    Fabian Weykamp
    Kristin Lang
    Laila König
    Katja Lindel
    Jan Tobias Oelmann-Avendano
    Johannes Krisam
    Andreas Schneeweiss
    Malte Ellerbrock
    Thomas Mielke
    Juliane Hörner-Rieber
    Klaus Herfarth
    Jürgen Debus
    Nathalie Arians
    Radiation Oncology, 18
  • [36] Health-related quality of life and patient-reported symptoms after postoperative proton beam radiotherapy of cervical and endometrial cancer: 2-year results of the prospective phase II APROVE-trial
    Meixner, Eva
    Wark, Antje
    Forster, Tobias
    Weykamp, Fabian
    Lang, Kristin
    Koenig, Laila
    Lindel, Katja
    Oelmann-Avendano, Jan Tobias
    Krisam, Johannes
    Schneeweiss, Andreas
    Ellerbrock, Malte
    Mielke, Thomas
    Hoerner-Rieber, Juliane
    Herfarth, Klaus
    Debus, Juergen
    Arians, Nathalie
    RADIATION ONCOLOGY, 2023, 18 (01)
  • [37] Long-term disease-free survival and health-related quality of life results of high-dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer treated in a community cancer center
    William, Raphael
    Mclaughlin, Pierre-Yves
    Pharand-Charbonneau, Mathieu
    Wright, Debbie Smith
    Haddad, Alain
    Gaudet, Marc
    BRACHYTHERAPY, 2025, 24 (01) : 54 - 61